The FDA has rejected Amneal Pharmaceuticals’ new drug application for IPX203, which the company hoped would be approved for treatment of Parkinson’s disease.
Read the full post on Becker's Hospital Review - Healthcare News
FDA rejects Amneal's Parkinson's drug
